EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Real-world effectiveness and predictors of treatment failure for eravacycline in patients with Acinetobacter baumannii or Klebsiella pneumoniae infections: a multicenter retrospective analysis

Yi Li, Qiaolian Yi, Menglan Zhou, Minya Lu, Yingchun Xu

Frontiers in Cellular and Infection Microbiology · 04.03.2026 · 16

DOI: 10.3389/fcimb.2026.1746200 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 04.03.2026. Verfasst von Yi Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beiji…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Klebsiella pneumoniae, Acinetobacter baumannii, Acinetobacter Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Eravacycline (ERV) is a novel synthetic fluorocycline antibiotic with broad-spectrum antibacterial efficacy against pathogens. This study aimed to investigate the clinical effectiveness of eravacycline and its correlation with minimum inhibitory concentrations (MICs) against infections caused by Acinetobacter baumannii or Klebsiella pneumoniae .

Methods

This retrospective multicenter study investigated the real-world use of ERV in 1,796 adults with infection caused by A. baumannii or K. pneumoniae in China. Antimicrobial susceptibility of strains and laboratory test results during treatment were analyzed. Microbiological and clinical outcomes were assessed at the end of treatment and day 30.

Results

The overall susceptibility rate to ERV was 96.0% (1,027/1,070), and around 98% of carbapenem-resistant isolates were susceptible to ERV. ERV had a 4-fold lower MIC 90 than tigecycline against both pathogens. At end of treatment, treatment success (microbiological eradication or clinical resolution) occurred in 82.6% (1,483/1,796) of the cohort with microbiological eradication achieved 76.1% (789/1,037). At day 30, infection cure was achieved in 83.57% (1,501/1,796) of the cases. Different ERV regimens (monotherapy or concomitant therapy) had no influence on the treatment and 30-day clinical outcomes. Multivariable analysis identified that elevated C-reactive protein (CRP) levels during treatment, bloodstream infection, sepsis and specific clinical interventions (e.g., central venous catheterization) were independent predictors of treatment failure.

Conclusions

The study highlights ERV’s utility in infection of A. baumannii or K. pneumoniae , especially carbapenem-resistant strains.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsKlebsiella pneumoniaeAcinetobacter baumanniiAcinetobacter InfectionsKlebsiella InfectionsTetracyclinesHumansRetrospective StudiesMicrobial Sensitivity TestsFemaleTreatment FailureChinaMaleMiddle AgedAgedAdultTreatment OutcomeAged, 80 and over

Stichwörter der Autor:innen

Acinetobacter baumanniiKlebsiella pneumoniaeantimicrobial stewardshipcarbapenemeravacycline

Substanzen

Anti-Bacterial AgentseravacyclineTetracyclines

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Zitieren

APA

Li, Y., Yi, Q., Zhou, M., Lu, M., & Xu, Y. (2026). Real-world effectiveness and predictors of treatment failure for eravacycline in patients with Acinetobacter baumannii or Klebsiella pneumoniae infections: a multicenter retrospective analysis. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1746200

Vancouver

Li Y, Yi Q, Zhou M, Lu M, Xu Y. Real-world effectiveness and predictors of treatment failure for eravacycline in patients with Acinetobacter baumannii or Klebsiella pneumoniae infections: a multicenter retrospective analysis. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1746200

BibTeX
@article{Li2026,
  author = {Li, Yi and Yi, Qiaolian and Zhou, Menglan and Lu, Minya and Xu, Yingchun},
  title = {Real-world effectiveness and predictors of treatment failure for eravacycline in patients with Acinetobacter baumannii or Klebsiella pneumoniae infections: a multicenter retrospective analysis},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fcimb.2026.1746200}
}
Kostenlos starten →